Key result
Blood measured biomarkers show potential for diagnostics and prognosis in non-ischemic cardiomyopathies, but reliable data for predicting sudden cardiac death are still lacking.
Why the study?
Can blood measured biomarkers improve diagnostics, prognosis, and prediction of sudden cardiac death in patients with non-ischemic cardiomyopathies?
Can blood measured biomarkers improve diagnostics, prognosis, and prediction of sudden cardiac death in patients with non-ischemic cardiomyopathies?
Blood biomarkers show promise in improving risk stratification for sudden cardiac death and managing non-ischemic cardiomyopathies, but further research is needed for reliable clinical integration.
No takes yet. Share an insight, caveat, or question.
Biomarkers may aid non-ischemic cardiomyopathy diagnosis and prognosis; leaves open reliable sudden cardiac death prediction.
Kruska et al. (2017) conducted a review in Non-ischemic cardiomyopathies and sudden cardiac death. Blood measured biomarkers was evaluated. Blood measured biomarkers show potential for diagnostics and prognosis in non-ischemic cardiomyopathies, but reliable data for predicting sudden cardiac death are still lacking.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: